MYOKARDIA,INC. (NASDAQ:MYOK) Files An 8-K Other EventsItem 8.01 Other Events.
On September27, 2017, MyoKardia, Inc. (the “Company”) issued a press release providing an update on the clinical progress of the Company’s product candidate, MYK-491 (the “Press Release”). A copy of the Press Release is filed herewith as Exhibit 99.1 and is incorporated herein by reference.
Item 8.01. Financial Statements and Exhibits.
(d) Exhibits
|
ExhibitNo. |
Description |
| 99.1 | Press Release, dated September 27, 2017 |
MyoKardia Inc ExhibitEX-99.1 2 d420516dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MyoKardia Provides Update on MYK-491 Clinical Progress Single Ascending Dose Trial in Healthy Volunteers Continues Enrollment in Order to Refine Exposure-Activity-Relationship; Topline Data Expected by Early 2018 Next Trial of MYK-491 in DCM Patients Expected to Initiate by Year-End SOUTH SAN FRANCISCO,…To view the full exhibit click here
About MYOKARDIA,INC. (NASDAQ:MYOK)
MyoKardia, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics. Its pipeline includes over four therapeutic programs for the chronic treatment of over two forms of heritable cardiomyopathy-hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). Its lead product candidate, MYK-461, is an orally-administered small molecule that reduces cardiac muscle contractility leading to HCM. In preclinical models of HCM, MYK-461 has been shown to prevent and reverse disease progression and to reduce left ventricular outflow tract obstruction. It is evaluating MYK-461 in over three Phase I clinical trials, including approximately two single ascending dose (SAD) trials and over one multiple ascending dose (MAD) trial.
